Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints Elliott Sigal to Board

Bristol-Myers Squibb has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee

Bristol-Myers Squibb (BMS) has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee.

Sigal joined BMS in 1997 as vice president of applied genomics. He has since served in critical leadership roles within R&D, including drug discovery and development. During Sigal's time as chief scientific officer, BMS achieved eight new drug approvals and filled the drug pipeline with numerous mid- and late-stage assets, five of which could be approved by 2012. 

"We are very excited to have Elliott join our Board," said James M Cornelius, chairman, Bristol-Myers Squibb. "Under his leadership, our R&D organisation has become one of the most productive in the industry. Today's appointment recognises his great contribution to the company." 
Sigal has held the role of executive vice president, chief scientific officer and president, BMS research and development since 2004. He reports to Lamberto Andreotti, CEO, BMS.

2nd March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...

Infographics